Associations - HRAS mutation

HRAS mutation HRAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	HRAS mutation HRAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline	cabozantinib capsule Sensitive: A2 - Guideline
HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	tipifarnib Sensitive: B - Late Trials	tipifarnib Sensitive: B - Late Trials
HRAS mutation HRAS mutation	Urothelial Cancer Urothelial Cancer	HRAS mutation HRAS mutation	Urothelial Cancer Urothelial Cancer	tipifarnib Sensitive: C2 – Inclusion Criteria	tipifarnib Sensitive: C2 – Inclusion Criteria
HRAS mutation HRAS mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	HRAS mutation HRAS mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	trametinib Sensitive: C2 – Inclusion Criteria	trametinib Sensitive: C2 – Inclusion Criteria
HRAS mutation HRAS mutation	Multiple Myeloma Multiple Myeloma	HRAS mutation HRAS mutation	Multiple Myeloma Multiple Myeloma	selinexor Sensitive: C3 – Early Trials	selinexor Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Acute Myelogenous Leukemia AML	HRAS mutation HRAS mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Colorectal Cancer CRC	HRAS mutation HRAS mutation	Colorectal Cancer CRC	sorafenib Sensitive: C3 – Early Trials	sorafenib Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Colorectal Cancer CRC	HRAS mutation HRAS mutation	Colorectal Cancer CRC	EGFR inhibitor Sensitive: C3 – Early Trials	EGFR inhibitor Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Acute Myelogenous Leukemia AML	HRAS mutation HRAS mutation	Acute Myelogenous Leukemia AML	venetoclax + ABBV-621 Sensitive: C3 – Early Trials	venetoclax + ABBV-621 Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Salivary Gland Cancer Salivary Gland Cancer	HRAS mutation HRAS mutation	Salivary Gland Cancer Salivary Gland Cancer	tipifarnib Sensitive: C3 – Early Trials	tipifarnib Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
HRAS mutation HRAS mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	HRAS mutation HRAS mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials	atezolizumab + cobimetinib Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Solid Tumor Solid Tumor	HRAS mutation HRAS mutation	Solid Tumor Solid Tumor	selumetinib Resistant: C3 – Early Trials	selumetinib Resistant: C3 – Early Trials
HRAS mutation HRAS mutation	Colorectal Cancer CRC	HRAS mutation HRAS mutation	Colorectal Cancer CRC	pembrolizumab + selinexor Sensitive: C3 – Early Trials	pembrolizumab + selinexor Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Melanoma Melanoma	HRAS mutation HRAS mutation	Melanoma Melanoma	cobimetinib + HM95573 Sensitive: C3 – Early Trials	cobimetinib + HM95573 Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Colorectal Cancer CRC	HRAS mutation HRAS mutation	Colorectal Cancer CRC	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
HRAS mutation HRAS mutation	Colorectal Cancer CRC	HRAS mutation HRAS mutation	Colorectal Cancer CRC	bevacizumab Resistant: C3 – Early Trials	bevacizumab Resistant: C3 – Early Trials
HRAS mutation HRAS mutation	Rectal Cancer Rectal Cancer	HRAS mutation HRAS mutation	Rectal Cancer Rectal Cancer	SOXIRI Sensitive: C3 – Early Trials	SOXIRI Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Rectal Cancer Rectal Cancer	HRAS mutation HRAS mutation	Rectal Cancer Rectal Cancer	FOLFOXIRI Sensitive: C3 – Early Trials	FOLFOXIRI Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Acute Myelogenous Leukemia AML	HRAS mutation HRAS mutation	Acute Myelogenous Leukemia AML	mTOR inhibitor Resistant: D – Preclinical	mTOR inhibitor Resistant: D – Preclinical
HRAS mutation HRAS mutation	Rhabdomyosarcoma Rhabdomyosarcoma	HRAS mutation HRAS mutation	Rhabdomyosarcoma Rhabdomyosarcoma	tipifarnib Sensitive: D – Preclinical	tipifarnib Sensitive: D – Preclinical
HRAS mutation HRAS mutation	Endometrial Cancer Endometrial Cancer	HRAS mutation HRAS mutation	Endometrial Cancer Endometrial Cancer	AZ 628 Sensitive: D – Preclinical	AZ 628 Sensitive: D – Preclinical
HRAS mutation HRAS mutation	Endometrial Cancer Endometrial Cancer	HRAS mutation HRAS mutation	Endometrial Cancer Endometrial Cancer	PD-0325901 Sensitive: D – Preclinical	PD-0325901 Sensitive: D – Preclinical
HRAS mutation HRAS mutation	Bladder Cancer Bladder Cancer	HRAS mutation HRAS mutation	Bladder Cancer Bladder Cancer	FL118 Sensitive: D – Preclinical	FL118 Sensitive: D – Preclinical